Unity Biotechnology: ARCH Venture reports 0% in 13G/A

Unity Biotechnology, Inc. received an amended Schedule 13G/A (Amendment No. 4) from ARCH-affiliated entities and managers stating they beneficially own 0 shares and represent 0% of the common stock (CUSIP 91381U200).

Rhea-AI Filing Summary

Unity Biotechnology, Inc. received an amended Schedule 13G/A (Amendment No. 4) from ARCH-affiliated entities and managers stating they beneficially own 0 shares and represent 0% of the common stock (CUSIP 91381U200). The date of the event requiring the filing is 09/30/2025.

Each reporting person—ARCH Venture Fund VII, L.P.; ARCH Venture Fund VIII Overage, L.P.; related ARCH Venture Partners entities; and individuals Keith Crandell, Robert Nelsen, and Clinton Bybee—reports 0 sole/shared voting power and 0 sole/shared dispositive power.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did UNBX disclose in this Schedule 13G/A?

ARCH-affiliated reporting persons filed Amendment No. 4 reporting 0 shares beneficially owned, representing 0% of Unity Biotechnology’s common stock.

What is the event date for this ownership report on UNBX?

The date of the event requiring the filing is 09/30/2025.

Which securities are covered for UNBX?

Common Stock, par value $0.0001 per share; CUSIP 91381U200.

Who are the reporting persons in the UNBX 13G/A?

ARCH Venture Fund VII, L.P.; ARCH Venture Fund VIII Overage, L.P.; ARCH Venture Partners VII, L.P.; ARCH Venture Partners VII, LLC; ARCH Venture Partners VIII, LLC; and individuals Keith Crandell, Robert Nelsen, Clinton Bybee.

What voting and dispositive powers were reported for UNBX?

Each reporting person disclosed 0 sole/shared voting power and 0 sole/shared dispositive power.

What percentage of UNBX does the group report owning?

They report owning 0% of the class.

Where is Unity Biotechnology’s principal executive office?

124 Washington Street, Suite 101, Foxborough, MA 02035.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/14/2025 - 04:30 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 4)

UNITY BIOTECHNOLOGY, INC.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

91381U200

(CUSIP Number)

09/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 91381U200

1

Names of Reporting Persons

ARCH Venture Fund VII, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP No. 91381U200

1

Names of Reporting Persons

ARCH Venture Fund VIII Overage, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP No. 91381U200

1

Names of Reporting Persons

ARCH Venture Partners VII, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP No. 91381U200

1

Names of Reporting Persons

ARCH Venture Partners VII, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 91381U200

1

Names of Reporting Persons

ARCH Venture Partners VIII, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 91381U200

1

Names of Reporting Persons

Keith Crandell

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP No. 91381U200

1

Names of Reporting Persons

Clinton Bybee

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP No. 91381U200

1

Names of Reporting Persons

Robert Nelsen

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: UNITY BIOTECHNOLOGY, INC.
(b)	Address of issuer's principal executive offices: 124 Washington Street, Suite 101, Foxborough, MA 02035
Item 2.
(a)	Name of person filing: ARCH Venture Fund VII, L.P. ("ARCH Venture Fund VII"); ARCH Venture Fund VIII Overage, L.P. ("AVF VIII Overage LP"); ARCH Venture Partners VII, L.P. ("AVP VII LP"); ARCH Venture Partners VII, LLC ("AVP VII LLC"); ARCH Venture Partners VIII, LLC ("AVP VIII LLC") (collectively, the "Reporting Entities" and individually, each a "Reporting Entity"); and Keith Crandell ("Crandell"), Robert Nelsen ("Nelsen") and Clinton Bybee ("Bybee") (collectively, the "Managing Directors" and individually, each a "Managing Director"). The Reporting Entities and the Managing Directors collectively are referred to as the "Reporting Persons".
(b)	Address or principal business office or, if none, residence: 8755 W. Higgins Avenue, Suite 1025, Chicago, IL 60631
(c)	Citizenship: ARCH Venture Fund VII, AVF VIII Overage LP and AVP VIII LP are limited partnerships organized under the laws of the State of Delaware. AVP VII LLC and AVP VIII LLC are limited liability companies organized under the laws of the State of Delaware. Each Managing Director is a US citizen.
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 91381U200
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Not applicable.
(b)	Percent of class: 0%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

ARCH Venture Fund VII, L.P.

Signature:	/s/ ARCH Venture Partners VII, L.P.
Name/Title:	its General Partner
Date:	11/14/2025

Signature:	ARCH Venture Partners VII, LLC
Name/Title:	its General Partner
Date:	11/14/2025

Signature:	/s/ Mark McDonnell*
Name/Title:	Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
Date:	11/14/2025

ARCH Venture Fund VIII Overage, L.P.

Signature:	ARCH Venture Partners VIII, LLC
Name/Title:	its General Partner
Date:	11/14/2025

Signature:	/s/ Mark McDonnell*
Name/Title:	Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
Date:	11/14/2025

ARCH Venture Partners VII, L.P.

Signature:	/s/ ARCH Venture Parnters VII, LLC
Name/Title:	its General Partner
Date:	11/14/2025

Signature:	/s/ Mark McDonnell*
Name/Title:	Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
Date:	11/14/2025

ARCH Venture Partners VII, LLC

Signature:	/s/ Mark McDonnell*
Name/Title:	Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
Date:	11/14/2025

ARCH Venture Partners VIII, LLC

Signature:	/s/ Mark McDonnell*
Name/Title:	Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
Date:	11/14/2025

Keith Crandell

Signature:	/s/ Mark McDonnell*
Name/Title:	Mark McDonnell, as Attorney-in-Fact for Keith Crandell
Date:	11/14/2025

Clinton Bybee

Signature:	/s/ Mark McDonnell*
Name/Title:	Mark McDonnell, as Attorney-in-Fact for Clinton Bybee
Date:	11/14/2025

Robert Nelsen

Signature:	/s/ Mark McDonnell*
Name/Title:	Mark McDonnell, as Attorney-in-Fact for Robert Nelsen
Date:	11/14/2025

Comments accompanying signature: * This Schedule 13G was executed by Mark McDonnell pursuant to Powers of Attorney dated May 7, 2013 and July 26, 2017, filed as Exhibit 2.0 and Exhibit 2.1 to the Schedule 13G filed with the Securities and Exchange Commission on February 14, 2019 and incorporated herein by reference.